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classified according to the first drug dispensing during 6 months from the discharge 
date. Patients were categorized in low ischemic stroke (CHA2DS2-VASc) (LR, score= 0), 
moderate-risk (MR, score= 1), high-risk (HR, score≥ 2).Multivariable logistic regression 
was used to evaluate the associations between ischemic stroke and bleeding (HAS-
BLED) risk with the choice of non-vitamin K antagonist oral anticoagulants (NOACs) 
versus vitamin K antagonists (VKAs) therapy. Results: A total of 1,963 patients were 
identified: 4.9% LR, 7.6% MR and 87.5% HR patients. Overall, 36.4% of patients were 
not treated (LR: 56.7%, MR: 55.0%, HR: 33.7%patients). Among patients treated, VKA in 
monotherapy was prescribed to 26.7% of the patients (LR: 23.8%, MR: 26.9%, HR: 26.8%), 
aspirin in monotherapy to 27.5% (LR: 31.0%, MR: 34.3%, HR: 27.0%), NOAC in mono-
therapy to 19.3% (LR: 23.8%, MR: 17.9%, HR: 19.2%), other antiplatelet in monotherapy 
to 19.4% (LR: 16.7%, MR: 13,4%, HR: 19.8%), and associations to 7.1% (LR: 4.8%, MR: 
7.5%, HR: 7.2%). The ischemic stroke and bleeding risks were not significantly associ-
ated with the choice of anticoagulant drug. ConClusions: High proportion of NVAF 
patients with moderate or high stroke risk did not receive antithrombotic therapy 
as recommended by guidelines. Moreover, aspirin was commonly prescribed even in 
HR patients. The risk stratification did not influence the choice of anticoagulant drug.
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objeCtives: The aim of this study was to assess the prevalence and characteristics 
of subjects with a recent ACS episode (in the year preceding statin prescription) 
appropriately treated with high-efficacy statins, and who have inadequate control of 
LDL-C levels, despite being adherent to treatment Methods: An observational ret-
rospective cohort analysis based on five Local Health Units administrative databases 
was conducted, for a total number of 1.2 Million beneficiaries. Patients who have 
been hospitalized with ICD9 code 410 in the year preceding their first statin pre-
scription (between January 1, 2011 and December 31, 2012) were included. Patients 
were characterized back 12 months from index date to assess appropriateness and 
adherence to statin treatment Results: Among patients with recent ACS enrolled 
(1’098 patients), 549 (50%) had no LDL-C determination, 335 (31%) and 214 (19%) 
displayed LDL-C under control and out of control, respectively. Among patients 
with uncontrolled LDL-C, 16 (7%) and 198 (93%) were not treated and treated with 
statins, respectively. Among patients with statins treatment, 27 (14%) and 171 (86%) 
were treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 115 (67%) and 56 (33%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 33.9% 
were less than 10% distant, 16.1% were 10-19% distant, 14.3% were 20-29% distant, 
12.5% were 30-39% distant and 23.2% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies are being marketed to 
address the unmet need in cholesterol statin-management of dyslipidaemia for 
uncontrolled patients. By projecting study percentages to the Italian population, 
the number of LDL-C measured patients with a recent ACS episode who are uncon-
trolled, despite being adherent to a high efficacy statin, would be around 6’524
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objeCtives: In Japan, real-world evidence regarding impact of obesity on the preva-
lence of hypertension is lacking. The objective of this study was to investigate the 
prevalence and treatment status of hypertension in obese patients, with a focus on 
resistant hypertension. Methods: This was a retrospective study using a Japanese 
healthcare database composed of annual health checkup and claims data (MinaCare 
Co. Ltd.). Subjects aged > = 20 years at 2012 health checkup with 2 years (2011/2012) of 
checkups were selected for the study. Diagnosed hypertensive subjects (ICD-10 codes 
I10-I15) who were prescribed with antihypertensive medications within 1 year prior to 
checkup were defined as “treated”. Resistant hypertension was defined as uncontrolled 
hypertension (SBP/DBP> = 140/90mmHg) with 3 classes of antihypertensives including 
diuretics, or the use of > = 4 classes. Results: A total of 462,323 subjects (32% female, 
68% male) were analyzed. The age category 40-< 50 years accounted for the largest 
proportion (35%) of the sample. The mean BMI was 21.8/23.7 and the proportion of 
obese subjects (BMI> = 25) was 16.0%/29.9% (female/male). Approximately 10.4% of the 
subjects were “treated”. For each age, sex, and treatment category, the prevalence of 
hypertension (defined as SBP/DBP> = 140/90mmHg or “treated”) increased with increas-
ing BMI. In particular, males in 40-< 50 age category, odds-ratio for the prevalence of 
hypertension versus BMI 18.5-< 25 were 0.601, 3.607, 7.405, 15.445 for BMI categories 
< 18.5, 25-< 30, 30-< 35, 35-< 40, 40-, respectively. The prevalence of resistant hyperten-
sion among those diagnosed and prescribed with antihypertensives was consistently 
higher for obese subjects (vs non-obese) for each sex and age category; in particular, it 
was 4.1% (obese) vs 8.7% (non-obese) for males in 40-< 50 age category. ConClusions: 
We demonstrated that prevalence of resistant hypertension as well as that of hyper-
tension increased with increasing BMI using healthcare database in Japan. These 
results reconfirm the impact of obesity in the treatment and control of hypertension.
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objeCtives: The aim of this study was to assess the prevalence and character-
istics of subjects appropriately treated with high-efficacy statins, and who have 
and iloprost were 31% to 22% and 26% to 10%, respectively. Use of other PAH-specific 
medication among PGI2 users increased over time, from 62% in CY2010 to 69% in 
CY2014. Mean (standard deviation [SD]) annualized PGI2 costs ranged from $99,919 
($100,139) to $118,861 ($136,493) per CY. Use of parenteral PGI2 decreased over time 
(from 63.2% in CY2010 to 52.4% in CY2014), whereas non-parenteral PGI2 usage 
increased (from 39.7% to 49.5%). Other PAH-specific medications were used in the 
same CY for 74.1%–77.6% of non-parenteral PGI2 users, compared to 54.4%–64.3% 
of parenteral PGI2 users. Mean parenteral PGI2 costs in CY2010 were twice those 
of non-parenteral PGI2. By CY2014, parenteral PGI2 costs were 8% lower than non-
parenteral costs. Mean (SD) PAH-related costs ranged from $189,763 ($167,329) dur-
ing CY2010 to $199,336 ($194,638) during CY2013. ConClusions: While overall use 
of PGI2 was constant over the five-year period, our findings suggest a shift towards 
non-parenteral PGI2 and PGI2 combination therapy in clinical practice.
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objeCtives: Hypertension is one of the major risk factors for occurrence cardiovas-
cular disease. Drugs of the first choice in the treatment of hypertension are: diuretics, 
beta adrenergic blockers, calcium channel blockers, angiotensin converting enzyme 
inhibitors and inhibitors of angiotensin II receptor. Fixed combinations of antihyper-
tensive drugs simplify treatment and enhance patient compliance. The aim of this 
study was to analyze consumption fixed combinations of drugs for the treatment of 
hypertension in the Republic of Serbia in the 2011-2012 year and to compared it with 
the results of Finland and Norway in the same period. Methods: Consumption of 
officinals is expressed by the number of defined daily doses per 1000 inhabitants per 
day (DDD) according to the anatomical therapeutic chemical classification. Data on 
consumption of drugs are taken from the official web site for the period 2007– 2012. 
year from the Agency for drugs and medical devices of Serbia, Finnish Medicines 
Agency Fima and Norwegian Institute of Public Health. Results:: Fixed combina-
tion of converting enzyme inhibitors with diuretics are most frequently used drugs 
in Serbia (2007 (18,86 DDD), 2008 (26,61 DDD), 2009 (30,77 DDD), 2010 (27,30 DDD), 2011 
(43,72 DDD) and 2012 (55,52 DDD)) compared with Norway and Finland. The use of 
these drugs is on the rise in Serbia. In the opposite side use of angiotensin II antago-
nists and diuretics in Serbia is significantly lower (2007 (0,10 DDD), 2008 (0,07 DDD), 
2009 (0,12 DDD), 2010 (0,19 DDD), 2011 (0,73 DDD) and 2012 (1,70 DDD)) compared with 
Norway and Finland. ConClusions: Based on the results, we concluded that the use 
of fixed combination of drugs in therapy of hypertension in Serbia must be modified. 
This research was supported by Provincial Secretariat for Science and Technological 
Development, Autonomous Province of Vojvodina project No 114-451-2458/2011 and 
by Ministry of Science, Republic of Serbia, project no 41012
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of individuals with diabetes at very high cardiovascular (CV) risk (patients with type 
2 or type 1 diabetes, with target organ damage, such as microalbuminuria - ESC/
EAS Guidelines 2011). Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database containing 
data on hospitalizations, prescriptions and diagnostic/outpatient visits). The index 
period lasted from January 1 to December 31, 2011. Results: Of the 2,989,512 sub-
jects identified, 101,217 patients (3.4%) had diabetes with very high CV risk. 82.9% 
were aged over 60 years. At 1-year follow-up, 46.1% were prescribed statin therapy, 
of which 56.9% being prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, 
Rosuvastatin 20, 40 mg/dL). Adherence to treatment (20% tolerability in one year 
follow-up treatment - CORE Study 2013) was higher among high intensity statin users 
compared to low intensity statin users (53.6% vs 40.1%). Over the 1-year follow-up 
period, 23,116 patients (22.8%) were hospitalized for any CV events. The average 
yearly cost per patient, on the high risk diabetic patients, supported by NHS was 
3,001 € /year (hospitalizations: 1,555€ ; drugs: 998€ ; diagnostic and outpatient vis-
its: 449€ ). ConClusions: In this community hospital setting, diabetic patients at 
very high risk of CV were frequently hospitalized for CV events. Although at high 
risk, less than 50% of patients was prescribed on statin therapy and adherence was 
suboptimal. Individuals with diabetes at very high CV risk utilize a significant por-
tion of economic resources, hospitalization being the main cost driver. Local Health 
Authorities together with Physicians and Patient Associations are working to close 
the gap between the existing evidence-based recommendations and current clinical 
practice which could result in a reduction of both diabetes morbidity and health cost.
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PatiEnts in rEal-world PraCtiCE
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objeCtives: To assess the level of adherence to the guidelines for the preven-
tion of thromboembolic risk in patients with Non-Valvular Atrial Fibrillation 
(NVAF). Methods: A population-based cohort study was conducted using admin-
istrative data from a local health authority in the Campania Region (~1,000,000 
inhabitants). NVAF was defined as one or more claims for atrial fibrillation (ICD-
9-CM code 427.31) between July, 2013 and June, 2014 where none of the claims were 
associated with cardioversion or cardiac ablation during the identification period 
and there was no evidence of valve-related diagnoses or procedures. The cohort was 
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2007-2011, with a 2-year history and a 3-year follow-up censored at the end of 2012, 
was designed in the EGB, a 1/97 random sample of the French national healthcare 
claims and hospitalization database. AF population was defined as patients with full 
coverage for AF, hospitalization or probabilistic AF information in the database, and 
without other probable cause of VKA prescription. NVAF population was defined as 
patients of the AF population without valvular disease history. Outcomes were the 
first hospitalization for bleeding, arterial thrombotic event (ATE), acute coronary 
syndrome (ACS), and death. Incidence rate of outcomes was estimated during VKA 
exposure. Results: Among 8,894 patients identified, 3,345 were classified in the 
AF population (3,977 person-years (PY)). Half were male (52%) with a mean age of 75 
years, 87% had a CHA2DS2-VASc score ≥ 2, and 12% a HAS-BLED score > 3. The inci-
dence rate of bleeding was 28 patients (95%CI [23-34]) for 1,000 PY exposed to VKA, 
including 6 [3-8] cerebral, 10 [7-13] digestive, and 14 [10-17] other bleeds. Incidence 
rates were 16 [12-20] for ACS, 15 [11-18] for ATE, and 38 [32-44] deaths for 1 000 PY 
exposed to VKA. Patient characteristics and incidence rates were very close for the 
2 818 patients with NVAF population criteria (3,367 PY). For this last population, 
incidence rates were 28 [22-34] for bleeding, 16 [12-20] for ACS, 15 [11-19] for ATE, and 
35 [29-41] deaths for 1 000 PY exposed to VKA. ConClusions: This study provides 
background reference for bleeding, ischemic events, and deaths before introduc-
tion of DOAC for NVAF with quite same frequency for AF and NVAF populations.
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objeCtives: Genetic factors have a great impact on the therapeutic dose of warfarin, 
a commonly prescribed anticoagulant. We still don’t consider them when prescrib-
ing warfarin, despite the high incidence of major and minor gastrointestinal (GI) 
bleeds. We evaluated the potential differential impact of warfarin-related GI bleeds 
risk factors according to the partient’s genetic profile. Methods: This study is based 
on a prospective cohort of new warfarin-users whose objectives were to assess the 
genetic, clinical and environmental risks associated with the effectiveness and safety 
of warfarin. Data was collected on 1069 patients who began the treatment between 
May 2010 and July 2013. Patients were followed-up each three months up to a year. 
The outcomes were minor and major GI bleeds. We used a multivariate Cox regres-
sion analysis. Results: Mean age was 70.8, 61.8% of patients were men, 68.4% had 
a history of hypertension and 60.8% of dyslipidemia and 76.4% had atrial fibrillation 
as a primary indication for warfarin. Overall, 4.8% of patients reported ≥ 1 minor GI 
bleed and 1.6% reported ≥ 1 major GI bleed. Patients with ≥ 1 polymorphism on both 
the CYP2C9 and the VKORC1 were significantly more at risk of having a major GI bleed 
(HR 10.72; p= 0.023). Patients with a history of MI or angina were at risk of having both 
minor and major GI bleeds (HR= 1.73 and HR= 2.63; p< 0.05). The impact of MI and 
angina disappeared for patients with no SNP on the CYP2C9 gene but was higher for 
patients with ≥ 1 SNP (HR= 2.44 and HR= 5.26, p< 0.05). ConClusions: Our results 
suggest an interaction between MI or angina history and the occurrence of major 
and minor GI bleeds, especially in patients with ≥ 1 polymorphism on the CYP2C9 
gene. Further analysis including concomitant drug use would help clarify clinical 
guidelines for this population and underlie the potential benefit of genetic testings.
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objeCtives: Heart failure (HF) affects 1.6 million people in Brazil. About 30%-40% 
progress to death in a year. This study aims to report 1-year retrospective analyses of 
hospital readmissions and mortality patterns associated to HF or all-other causes (OC) 
in a Brazilian cohort of patients with HF. Methods: Brazilian Hospital Information 
System (SIH/SUS) database was used to collect hospital readmissions and mortality 
data associated to HF or OC, according to ICD-10 codes (I50.0 and I50.9, and “others”, 
respectively). Patients were followed during 1 year (January-December 2014, regard-
less the entry data). Eligible criteria included patients with one previous HF hospital 
admission. Results: A cohort of 21,015 patients was considered eligible. No HF or OC 
hospital readmissions were observed for 13,050 (62%) and 5,241 (25%) patients, respec-
tively. For HF, 1, 2, 3, 4, and 5 re-hospitalizations were observed for 6,053, 1,255, 395, 152, 
and 59 patients. One patient required ten re-hospitalizations and the same occurred 
for 12 and 15 hospital readmissions. Therefore, about 38%, 9%, 3% and 1% of all 
patients had 1, 2, 3 or 4 hospital readmissions at least. OC readmissions showed higher 
number of patients for each amount of hospitalizations (11,046, 2,965, 989, 415, and 
184 for 1, 2, 3, 4, and 5, respectively). Seven patients required ten re-hospitalizations 
and 1 required 19. Compared to HF, OC showed approximately twice of all patients 
with 1 hospital readmission at least (75%). Mortality rate was 19.23%, 702 (3.34%) due 
to HF and 2,632 (12.52%) due to OC. ConClusions: The number of patients requiring 
hospitals readmissions for HF remain significant, despite available treatment options 
in Brazilian Public Healthcare System. OC results showed higher numbers, however, 
for this analysis all-other hospitalizations causes were included (except HF) indicat-
ing a high presence of comorbidities among this population and/or a misregistration 
at hospitalization time.
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inadequate control of LDL-C levels, despite being adherent to treatment Methods: 
An observational retrospective cohort analysis based on five Local Health Units 
administrative databases was conducted, for a total number of 1.2 Million benefi-
ciaries involved. Patients with at least one LDL-C measurement between January 
1, 2011 and December 31, 2012 were included. Patients were characterized back 12 
months to assess appropriateness and adherence to statin treatment Results: 
Among patients with LDL-C determination (1’218 patients), 578 (47%) and 640 (53%) 
displayed LDL-C under control and out of control, respectively. Among patients with 
uncontrolled LDL-C, 74 (12%) and 566 (88%) were not treated and treated with statins, 
respectively. Among patients with statins treatment, 188 (33%) and 378 (67%) were 
treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 225 (60%) and 153 (40%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 28% 
were less than 10% distant, 28.4% were 10-19% distant, 10.5% were 20-29% distant, 
11.1% were 30-39% distant and 24.8% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies - PCSK9 inhibitors - are 
being marketed to address the residual unmet need in cholesterol statin-manage-
ment of dyslipidaemia for uncontrolled patients. By projecting study percentages to 
the Italian population, the number of LDL-C patients who are uncontrolled, despite 
being adherent to a high efficacy statin, would be around 17’825
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objeCtives: To identify the characteristics and assess the treatment of patients 
diagnosed with ischemic stroke. It was also performed to compare the manage-
ment of ischaemic stroke between current practice with the recommended guide-
line. Methods: Retrospective reviews of the medical records of patients who were 
diagnosed with ischemic stroke at the medical record’s office in a teaching hospital 
from January 1, 2013 to December 31, 2013. Patients’ medication for the treatment of 
stroke at discharge were reviewed and identified. Results: A total of 198 patients 
were diagnosed with ischemic stroke. This was found to be higher in men 104 (52.5%). 
In this study of 198 patients, 108 (54.5%) patients were diagnosed with newly onset 
of stroke and 28 (14.1%) patients were diagnosed with recurrent stroke. The major 
co-morbidities identified were the combination of hypertension and diabetis mel-
litus and hypertension alone, which were seen in 45 (22.7%) patients and 39 (19.7%) 
patients respectively. Aspirin and statin were the most commonly prescribed agent, 
which were 170 (85.9%) and 182 (91.9%) respectively. ConClusions: Majority of our 
patients are male, Malay and in the age range of 50-59. These patients had underly-
ing hypertension and diabetes upon their diagnosis of ischemic stroke. Aspirin and 
statin were mostly prescribed and widely used to treat ischaemic stroke. The current 
guidelines appear to have some influence on the current practice of the management 
of ischemic stroke.
PCV43
EPidEmiologiCal burdEn and managEmEnt of hyPErCholEstErolEmia 
in high CardioVasCular risk PatiEnts in sPain: a ComPrEhEnsiVE 
PiCturE from a systEmatiC rEViEw of thE litEraturE
Callejo D1, Cuervo J2, Rubio M3, Subirà R3, de la Sierra A4, Pintó X5, Guijarro C6, López 
Miranda J7
1BAP Health Outcomes Research S.L., Oviedo, Spain, 2LASER ANALYTICA, Oviedo, Spain, 3Sanofi, 
Barcelona, Spain, 4University Hospital Mutua Terrassa, Terrassa, Spain, 5University Hospital 
Mutua Bellvitge, L’Hospitalet de Llobregat, Spain, 6University Hospital Alcorcón Foundation, 
Alcorcón, Spain, 7Reina Sofía Hospital, Córdoba, Spain
objeCtives: Elevated serum cholesterol levels are a well-known cause of car-
diovascular events. The objectives of this study were: to review the epidemiology 
of hypercholesterolemia in Spain; to detail the proportion of diagnosed patients 
undergoing pharmacological treatment (PhT); the degree of attained lipid con-
trol, and associated medical costs. Methods: A systematic literature review was 
carried out using Medline (pubmed) and Spanish databases as Medes and Biblioteca 
Virtual de la Salud. Manuscripts containing information on heterozygous familial hyper-
cholesterolemia (HeFH); hypercholesterolemia in primary prevention (PP) (diabetes mel-
litus or SCORE risk > 5) or secondary prevention (SP), published between January 2010 
and October 2014, were included. Results: Of the 1,947 published references initially 
retrieved, a full text review was done on 264 manuscripts and 120 were finally included. 
Prevalence of hypercholesterolemia ranged from 50%-84% in diabetics, 30%-60% in 
patients with high cardiovascular risk, 64%-74% with chronic coronary heart disease, 
33%-97% in acute coronary syndromes, 40%-70% in stroke patients, and 60%-80% in 
those with peripheral artery disease. Despite the finding that 30%-90% of patients were 
on pharmacological treatment, lipid control was found only in 15%-65% of cases in pri-
mary prevention and in 15%-56% of patients in secondary prevention. Among those with 
HeFH 95%-100% were treated but less than 16% achieved LDL-c target. ConClusions: 
An elevated prevalence of hypercholesterolemia can be seen in targeted groups at higher 
cardiovascular risk. Although most patients are receiving pharmacological treatment, 
rates of control continue to be low, both in primary and secondary prevention.
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objeCtives: To assess real-life outcomes in new Vitamin K antagonists (VKA) users 
for atrial fibrillation (AF), before introduction of direct oral anticoagulants (DOAC) 
for non-valvular AF (NVAF). Methods: Cohort study of new VKA users between 
